CagriSema: difference between revisions
Diff·revision 12 → 13·20:22, 9 Apr 2025
Difference between revision 12 and revision 13 of CagriSema. 3 lines changed; the page grew by 280 bytes.
| Revision 12 — 23:04, 20 Mar 2025 StubSorterBot (talk) bot: repair redlinked category 3,887 bytes ±0 | Revision 13 — 20:22, 9 Apr 2025 ImageReuseIris (talk) add the year of first marketing authorisation, with the regulator named 4,167 bytes +280 | ||
|---|---|---|---|
| 8 | }} | 8 | }} |
| 9 | {{hatnote|For the components, see [[Cagrilintide]] and [[Semaglutide]].}} | 9 | {{hatnote|For the components, see [[Cagrilintide]] and [[Semaglutide]].}} |
| + | 10 | {{update|talk=Phase 3 readouts}} | |
| 10 | 11 | ||
| 11 | '''CagriSema''' is an investigational fixed-ratio combination of the [[Amylin receptor agonist|amylin analogue]] [[Cagrilintide|cagrilintide]] and the [[GLP-1 receptor agonist]] [[Semaglutide|semaglutide]], co-formulated for weekly subcutaneous administration in a single injection. It is not approved for use in any indication.{{r|frias2023cagri}} | 12 | '''CagriSema''' is an investigational fixed-ratio combination of the [[Amylin receptor agonist|amylin analogue]] [[Cagrilintide|cagrilintide]] and the [[GLP-1 receptor agonist]] [[Semaglutide|semaglutide]], co-formulated for weekly subcutaneous administration in a single injection. It is not approved for use in any indication.{{r|frias2023cagri}} |
| ⋮ | ⋮ | ||
| 26 | 27 | ||
| 27 | That last point has attracted attention: an efficacy figure obtained when many participants remained on lower doses is not the same as an efficacy figure at the target dose, and the two interpretations of the result — that the ceiling was not reached, or that dose escalation is the practical limit — have different implications. | 28 | That last point has attracted attention: an efficacy figure obtained when many participants remained on lower doses is not the same as an efficacy figure at the target dose, and the two interpretations of the result — that the ceiling was not reached, or that dose escalation is the practical limit — have different implications. |
| + | 29 | ||
| + | 30 | The adverse-effect profile is that of the two components, dominated by gastrointestinal events. Whether combining two agents that both delay gastric emptying is additive for nausea is not directly addressed by the published designs.{{r|lau2021}} | |
| 28 | 31 | ||
| 29 | == References == | 32 | == References == |